This protocol applies to patients with metastatic pancreatic cancer who present with meaningful functional impairment, as reflected by ECOG performance status 2, Karnofsky Performance Status below 70, and/or a serum bilirubin level exceeding 1.5 times the upper limit of normal. This combination of findings defines the specific population for whom a tailored first-line approach is warranted.
Patients in this group exhibit reduced functional capacity and/or hepatic compromise that directly influences which systemic treatment can be safely initiated. ECOG PS 2 and/or KPS <70 indicate limited tolerance for intensive regimens, while elevated bilirubin may reflect biliary involvement or liver burden requiring specific consideration.
In this setting, first-line systemic chemotherapy is guided by performance status and hepatic function. A single-agent chemotherapy approach forms the basis of treatment. The complete regimen, dosing guidance, and clinical decision points are detailed in the full structured protocol.
Treatment efficacy is evaluated on a periodic basis, incorporating clinical status, CA 19-9 trajectory, and imaging findings. The protocol specifies the recommended evaluation intervals and criteria for response assessment or treatment adjustment.
DOI: 10.1016/j.annonc.2023.08.009
For patients with ECOG PS 2, KPS <70 and/or bilirubin level >1.5 times the ULN, gemcitabine monotherapy should be considered [I, A].
The efficacy of treatment should be typically evaluated every 8-12 weeks and should be based on clinical status, CA 19-9 trajectory and imaging [III, A].
View source ↗